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A B S T R A C T
Background: Volatile anaesthetics (VAs) are the most widely used compounds to induce reversible loss of con-
sciousness and maintain general anaesthesia during surgical interventions. Although the mechanism of their
action is not yet fully understood, it is generally believed, that VAs depress central nervous system functions
mainly through modulation of ion channels in the neuronal membrane, including 2-pore-domain K+ channels,
GABA and NMDA receptors. Recent research also reported their action on nociceptive and thermosensitive TRP
channels expressed in the peripheral nervous system, including TRPV1, TRPA1, and TRPM8. Here, we in-
vestigated the effect of VAs on TRPM3, a less characterized member of the thermosensitive TRP channels playing
a central role in noxious heat sensation.
Methods: We investigated the effect of VAs on the activity of recombinant and native TRPM3, by monitoring
changes in the intracellular Ca2+ concentration and measuring TRPM3-mediated transmembrane currents.
Results: All the investigated VAs (chloroform, halothane, isoflurane, sevoflurane) inhibited both the agonist-
induced (pregnenolone sulfate, CIM0216) and heat-activated Ca2+ signals and transmembrane currents in a
concentration dependent way in HEK293T cells overexpressing recombinant TRPM3. Among the tested VAs,
halothane was the most potent blocker (IC50 = 0.52 ± 0.05 mM). We also investigated the effect of VAs on
native TRPM3 channels expressed in sensory neurons of the dorsal root ganglia. While VAs activated certain
sensory neurons independently of TRPM3, they strongly and reversibly inhibited the agonist-induced TRPM3
activity.
Conclusions: These data provide a better insight into the molecular mechanism beyond the analgesic effect of
VAs and propose novel strategies to attenuate TRPM3 dependent nociception.
https://doi.org/10.1016/j.bcp.2020.113826
Received 25 November 2019; Accepted 22 January 2020
⁎ Corresponding author.
E-mail address: toth.istvan@med.unideb.hu (B.I. Tóth).
1 TB and BIT contributed equally to the work as senior authors.
2 0000-0002-8994-0132.
3 0000-0002-8517-6536.
4 0000-0003-4122-5639.
5 0000-0001-6046-8236.
6 0000-0001-5526-5821.
7 0000-0002-3770-6221.
8 0000-0002-4103-4333.
Biochemical Pharmacology 174 (2020) 113826
Available online 25 January 2020
0006-2952/ © 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/BY/4.0/).
T
1. Introduction
Volatile anaesthetics (VAs) are the most commonly used compounds
to maintain general anaesthesia during operation both in human ther-
apeutic interventions and in animal experiments [1]. Although the
exact mechanisms, whereby VAs cause a reversible loss of conscious-
ness are not yet fully understood, it is generally accepted that they
suppress the activity of the central nervous system by specifically tar-
geting cellular proteins, including several ion channels, among others.
A few of these ion channels, especially GABAA receptors and various K+
channels, are considered to play a central role in the general depression
of the central nervous system functions resulting in reversible loss of the
consciousness initiated by VAs [2–4]. However, VAs can also influence
several other ion channels, including voltage-gated Na+, K+ and Ca2+
channels [5,6]. Moreover, in recent years, their action on sensory
transient receptor potential (TRP) channels has also been reported.
TRP channels form a heterogeneous and multifunctional group in
the voltage gated-like superfamily of ion channels. The 6-transmem-
brane domain containing TRP proteins form non-specific, mostly Ca2+
permeable cationic channels, and are functional as homo- or hetero-
tetramers [7–9]. Most TRP channels are considered to function as
polymodal “cellular sensors” sensitive to diverse changes in the phy-
sico-chemical environment (e.g. temperature, pH, osmolarity, ionic
concentrations, endogenous mediators, external chemical irritants, etc.)
[10,11] and increasing body of evidence indicates their emerging roles
in various diseases [12,13]. In primary sensory neurons, the most
widely studied sensory TRPs are the thermosensitive TRPV1, TRPA1
and TRPM8 channels. Their versatile role in diverse (patho)physiolo-
gical sensory processes, including thermosensation, itch, pain (together
with different forms of hyperalgesia and allodynia), and inflammation
has inspired a plethora of research studies [14–21]. This in turn has
urged several pharmaceutical companies to find effective tools tar-
geting these thermosensitive TRP channels as potential novel drugs to
manage several, mostly pain related, clinical syndromes [22]. Recently,
VAs were also reported to activate TRPA1 [23,24], to sensitize TRPV1
[25] and also to modulate TRPM8 [26], and these results may explain
some adverse effects related to general anaesthesia.
TRPM3 was recently introduced as a novel thermosensitive noci-
ceptor TRP channel expressed by a large subset of primary sensory
neurons of the dorsal root and trigeminal ganglia (DRG and TG).
TRPM3 has an essential role in acute heat pain sensation [27], it con-
tributes to the development of inflammatory heat hyperalgesia and
transmits chemical pain sensation evoked by its endogenous steroid
ligand pregnenolone sulfate (PregS) [28]. The stimulation of TRPM3 by
certain ligands e.g. CIM0216, or special ligand combinations, e.g. co-
application of PregS and the antifungal agent clotrimazole revealed an
alternative ion permeation pathway beyond the main pore, which re-
sulted in a strong inward current at negative membrane potentials. This
unique current displays the general characteristics of the so-called
omega currents reported earlier in mutant K+ and Na+ channels, and
may have a high (patho)physiological relevance exacerbating TRPM3
related pain sensation [29–31]. The above results, together with the
fact that modulation of TRPM3 activity, in contrast with TRPV1, did not
induce any change in the core body temperature of experimental ani-
mals [28], introduce TRPM3 as an appealing drug target for novel
therapeutic interventions in pain related syndromes. However, in order
to exploit the putative therapeutic potential of TRPM3 as a potential
drug target, a better understanding of its regulation and pharmacolo-
gical interactions are of greatest importance.
In this study, we investigated the effect of VAs on recombinant and
native TRPM3 ion channels and found that they potently inhibit TRPM3
function. These results further enhance our knowledge about VAs’
mechanism of action and may contribute to the development of novel
analgesics targeting TRPM3.
2. Materials and methods
2.1. Cell culturing and isolation of sensory neurons
Native HEK293T cells, and HEK293T cells stably overexpressing the
mouse TRPM3α2 variant (HEK-M3 cells) were cultured as described
before [28]. In brief, cells were cultured in DMEM medium (Invitrogen,
Paisley, UK), supplemented with 10% foetal bovine serum, (In-
vitrogen), 50 U/ml penicillin, 50 μg/ml streptomycin (both from
ThermoFisher, Waltham, MA, USA), 10 mM Glutamax, Non-Essential-
Amino-Acids and 200 μg/ml Hygromycin (all from Invitrogen) at 37 °C.
Sensory neurons of dorsal root ganglia (DRGs) were obtained from
adult (8–12 week old) C57BL6 mice, as described before [28]. Briefly,
mice were euthanized by CO2, DRGs were isolated and digested with
collagenase and dispase (both from Invitrogen). Suspension of sensory
neurons was seeded on poly-L-lysine HBr (Sigma Aldrich, St.Louis, MO,
USA) coated glass bottom culture dishes (MatTek, Ashland, MA, USA)
and cultured in Neurobasal medium supplemented with 2% B-27 sup-
plement (both from Invitrogen), 2 mM L-glutamine, 100 µg/ml peni-
cillin/streptomycin (both from ThermoFisher), and 100 ng/ml ß-NGF
(Pepro Tech EC, Ltd., London, UK) at 37 °C in 5% CO2 containing at-
mosphere. Neurons were used for experiments within 24 to 36 h fol-
lowing isolation. We aimed at obtaining high number of sensory neu-
rons yielding n ≥ 50 neurons in each experimental group for highly
reliable statistical analysis. Therefore, respecting the 3R principles, we
established multiple primary sensory neuron cultures from an animal
and used them in independent measurements. Cultures were randomly
recruited into the different experimental groups, and cultures from 3
individual animals were recruited into each group. Altogether, 12 an-
imals were used for the study. All experimental procedures and animal
husbandry were conducted following the European Parliament and the
Council Directive (2010/63/EU) and national legislation.
2.2. Fluorescent Ca2+ measurements
Fluorescent measurement of cytoplasmic Ca2+ concentration in
HEK cells and in individual DRG neurons were performed according to
our previously optimized protocols: HEK-M3 cells were seeded in Poly-
L-Lysine HBr (Sigma-Aldrich) coated 96-well/clear-bottom plates
(Greiner Bio-One, Frickenhausen, Germany) at a density of 100,000
cells per well in normal cell culture medium and incubated overnight.
Next day, cells were loaded with 2 μM Fura-2-AM (Invitrogen) at 37 °C
for 30 min, and washed three times with Ca2+-buffer (150 mM NaCl,
5 mM KCl, 1 mM MgCl2x6H2O, 2 mM CaCl2x2H2O, 10 mM glucose
xH2O, 10 mM HEPES, pH 7.4 (all from Sigma-Aldrich)). The plates were
then placed into a FlexStation 3 fluorescent microplate reader
(Molecular Devices, Sunnyvale, CA, USA) and cytoplasmic Ca2+ con-
centration (reflected by the ratio of fluorescence measured at λEX1:
340 nm, λEX2: 380 nm, λEM: 516 nm (F340/F380)) was monitored during
application of compounds in various concentrations. During the mea-
surements, cells in a given well were exposed to only one given con-
centration of the agents. Measurements were carried out at ambient
temperature.
To determine the VAs’ effect on the temperature-evoked activation
of TRPM3, we used a Fluo-4 based assay and a QPCR system. HEK-M3
and non-transfected HEK293T cells were loaded with 2 µM Fluo-4-AM
(Invitrogen) for 30 min, then they were trypsinised and re-suspended in
Ca2+- buffer in the presence or absence of VAs and transferred into PCR
tubes with optical transparent cover (200.000 cells/tube, 200 μL).
Fluorescence was measured with a Stratagene Mx3005P QPCR instru-
ment (Agilent Technologies Santa Clara, CA, USA) using an appropriate
filter set while the well temperature was increased from 25 °C to 46 °C
in steps of 3 °C.
To measure cytoplasmic Ca2+ concentration in individual DRG
neurons, we used a microscope based calcium imaging system. On the
day after the isolation, DRG neurons were loaded with 2 µM Fluo-4-AM
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(Invitrogen) dissolved in normal Ca2+-buffer, then placed on the stage
of a Zeiss LSM 5 Live confocal fluorescent microscope (Carl Zeiss AG,
Oberkochen, Germany) and Fluo-4 loaded cells were captured with
constant settings in every 1 s (λEX: 488 nm, λEM: 516 nm). During the
measurements, cells were continuously perfused with Ca2+-buffer and
different compounds were applied via the perfusion. Data were pre-
sented as F1/F0, where F0 is the average fluorescence of the baseline
(before the first compound application) and F1 is the actual fluores-
cence. Experiments were performed at room temperature (21–22 °C).
2.3. Electrophysiology
HEK-M3 cells were seeded to 12 mm glass coverslips previously
coated with poly-L-lysine HBr (Sigma-Aldrich) and whole cell patch
clamp measurements were carried out by using an Axopatch 1.D am-
plifier and Clampex 10.2 software (Molecular Devices). Pipettes with
final resistances of 2–5 MΩ were fabricated and filled with intracellular
solution containing 100 mM aspartic acid, 45 mM CsCl, 1.144 mM
MgCl2, 10 mM HEPES, and 10 mM EGTA (all from Sigma-Aldrich). pH
was adjusted to 7.2 using CsOH (VWR, Radnor, PE, USA). Experiments
were performed in a bath solution composed of 150 mM NaCl, 1 mM
MgCl2, and 10 mM HEPES buffered to pH 7.4 (NaOH) (all from Sigma-
Aldrich). To record TRPM3 mediated currents, the holding potential
was 0 mV and cells were ramped every 2 s from −150 to +150 mV
over the course of 200 ms. Recorded data were analysed and plotted
using Origin 9.0 software (OriginLab Corporation, Northampton, MA,
USA).
2.4. Preparation of working solutions of VAs
10 mM stock solutions of VAs were prepared in extracellular solu-
tion by a rigorous overnight stirring in air-tight closed vials. From these
stock solutions, fresh dilutions of the final working solutions were
prepared and used for measurements within 45 min. If needed, new
working solutions were diluted in every 30 min.
2.5. Gas chromatography/mass spectrometry (GC/MS)
The stability of the stock solutions of VAs in an open, freely venti-
lating system was checked by GC/MS. Stock solutions prepared as de-
scribed above were kept in an open vial at room temperature for 45 min
simulating the conditions in an open perfusion system used for patch
clamp and Ca2+ measurements. During this incubation time, samples
were taken at different time points and subjected for analysis im-
mediately. The active agents in the samples were identified by a GC/MS
method using an Agilent 7980B-5977A instrument (Agilent
Technologies, Santa Clara, CA, USA) at the Toxicology Laboratory of
the Institute of Forensic Medicine of the University of Debrecen. The
injection volume was 0.2 µL, and the injector temperature was 250 °C.
The applied capillary column was a J&W DB-35MS UI,
30 m × 0,25 mm × 0,25 µm. The detection parameters were the fol-
lowings: Sampling: split; split ratio: 20:1. Oven temperature program:
65 °C (2 min. hold time), heating: 50 °C/min to 230 °C; Interface:
280 °C; MS source: 230 °C; Ionization: EI; Detection mode: SCAN. The
‘area under curve’ of the specific peaks were determined in arbitrary
units and normalized to that of obtained from the sample taken at the
beginning (0 min) of the incubation.
2.6. Chemicals
Chloroform and halothane were obtained from Sigma Aldrich, iso-
flurane (sold as Vetflurane) was from Virbac (Carros, France) and se-
voflurane from AbbVie Inc. (North Chicago, IL, USA). Pregnenolone
sulphate (PregS), allyl isothiocyanate (AITC), capsaicin, thymol,
CIM0216 were obtained from Tocris Bioscience (Bristol, UK).
Isosakuranetin was obtained from Carl Roth (Karlsruhe, Germany).
Working solutions of VAs were prepared as described above. All other
drugs were prepared as stock solutions in dimethyl sulfoxide (DMSO),
and then diluted into extracellular solutions to reach the desired final
concentration. Concentration of the vehicle (DMSO) in the final
working solutions was 0.1%.
2.7. Curve fitting
Logistic dose-response curves were fitted using the equation
y = A2 + (A1 − A2)/(1 + (x/x0)^p) where the calculated parameters
are: A1: initial value (ymin), A2: final value (ymax), x0: center (EC50) and
p is the calculated power. Fittings were carried out and parameters
were calculated using Origin 9.0 (OriginLab Corporation).
2.8. Data and statistical analysis
Electrophysiological data were analysed using ClampFit 10.0 soft-
ware (Axon Instruments, Foster City, CA, USA). IBM SPSS Statistics 23.0
(IBM Corporation. Armonk, NY, USA) and Origin 9.0 (OriginLab
Corporation) were used for statistical analysis and data display. When
testing antagonistic effect of isosakuranetin, agonist induced Ca2+
signals in the presence and absence of isosakuranetin were compared
pairwise by two-tailed Student’s t-test for independent samples. To
control unwanted variances of measured currents between HEK-M3
cells, TRPM3 currents measured in the presence of VAs were normal-
ized, and compared to the agonist induced current (considered as
100%) in the same cell and two-tailed Student’s t-test for one sample
was used for statistical evaluation. In case of Ca2+ signals recorded on
sensory neurons, if it is not mentioned otherwise, signal amplitudes
were normalized to the 1st agonist evoked signal, considered as 100%,
to control variances experienced between individual neurons. Then,
data were subjected for statistical analysis using one-way ANOVA with
Dunnett post-hoc test to compare the effect of VAs to vehicle control. In
every case, P < 0.05 was regarded as showing significant differences
between group means. All data are presented as mean ± SD.
3. Results
3.1. VAs formed stabile solutions
In our study, we investigated the effect of VAs with various chemical
structures (Fig. 1a) on TRPM3 ion channel functions. Due to their vo-
latile and lipophilic nature, we assumed that it might be challenging to
prepare a stabile aqueous solution of VAs suitable for measurements,
although they reportedly can be solved>10 mM in water at 25 °C [32].
Therefore, we aimed at testing the stability of the stock solutions of VAs
applied in an open, freely ventilating system mimicking the conditions
in our perfusion and liquid handling systems used in the experiments.
For this, we performed GC/MS measurements on 10 mM stock solutions
of the VAs, which were prepared by rigorous overnight stirring in an
airtight vial, as described in the Materials and methods. The con-
centration of the stock solutions in open vials did not change drama-
tically during 45 min (Fig. 1b). Therefore, working solutions were
freshly prepared from 10 mM stock solutions stored in airtight vials and
used for measurements within 30 min. After 30 min, new working so-
lutions were prepared.
3.2. VAs inhibited chemical agonist induced activation of recombinant
TRPM3
First, we investigated the effect of VAs on recombinant TRPM3 by
carrying out Ca2+ measurements on HEK-M3 cells. During the mea-
surements, we applied various concentrations of VAs followed by the
application of TRPM3 agonists PregS or CIM0216 in the continuous
presence of VAs, as shown in Fig. 2a. This experimental design enabled
us to investigate both potential activating and inhibiting effect of VAs.
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We found that none of the investigated VAs activated the recombinant
TRPM3, whereas each of them inhibited the TRPM3-mediated Ca2+
signals evoked by the endogenous TRPM3 agonist PregS and by the
more potent synthetic TRPM3 agonist CIM0216 [30] in a dose depen-
dent manner (Fig. 2a-c). The IC50 values for halothane, chloroform,
isoflurane, and sevoflurane were (mean ± SEM) 0.52 ± 0.05 mM,
1.67 ± 0.03 mM, 1.09 ± 1.49 mM and, 3.83 ± 2.39 mM , respec-
tively, when TRPM3 was activated by 10 µM PregS (Fig. 2b), while the
IC50 values were 1.52 ± 0.05 mM, 1.64 ± 0.25 mM,
2.71 ± 0.88 mM and, 2.0 ± 0.28 mM when activated by 3 µM
CIM0216, respectively (Fig. 2c). Moreover, the EC50 value of PregS was
shifted from 0.37 ± 11 µM to 19.33 ± 4.24 µM (~51× fold),
2.13 ± 0.35 µM (~6× fold), 3.49 ± 1.3 µM (~8× fold), and
6.14 ± 6.39 µM (~15× fold) by 1 mM halothane, chloroform, iso-
flurane, and sevoflurane, respectively (Fig. 2d).
Although halothane was found to be the most potent inhibitor of
TRPM3 among the tested VAs, it also evoked robust Ca2+ transients
when applied alone at high concentrations (≥5 mM) (Fig. 3a). This
stimulatory effect of halothane was found to be independent of TRPM3,
because (i) it was equally observed in native HEK293T cells and HEK-
M3 cells (Fig. 3a-b) and (ii) the halothane-induced Ca2+ signals were
not inhibited by the TRPM3 antagonist isosakuranetin (Fig. 3c). It is
important to mention that the commercially available halothane ap-
plied in the current study also contained ca. 150 ppm thymol, as sta-
bilizer resulting in ca. 0.75 µM thymol in the most concentrated (5 mM)
halothane working solution tested. Since thymol was reported to be an
activator of TRPV3 [33,34] and TRPA1 [35], other thermosensitive
members of TRP family, we also investigated the effect of thymol on
TRPM3, to clarify its potential contribution to the effect of halothane.
Our results indicated that thymol applied at concentrations up to
300 µM did not affect TRPM3 functions: it neither activated HEK-M3
cells nor inhibited their activation evoked by PregS (Fig. 3d).
3.3. VAs inhibited the heat-evoked activation of TRPM3
Next, we tested whether the VAs influence activation of TRPM3 by
thermal stimuli, in addition to their effect on ligand-induced activation
of the channel. HEK-M3 cells were challenged by precise temperature
steps using a Quantitative real-time PCR instrument, and the in-
tracellular Ca2+ concentration was monitored in the presence of VAs at
various concentrations. Our results revealed that VAs also inhibited
warming-induced activation of TRPM3: the obtained IC50 values of
halothane, chloroform, isoflurane, and sevoflurane were
1.08 ± 0.58 mM, 1.50 ± 0.63 mM, 1.64 ± 0.59 mM, and
1.83 ± 0.63 mM, respectively, when cells were heated from 37 to
43 °C (Fig. 4).
3.4. VAs inhibited TRPM3 mediated transmembrane currents
In whole-cell patch-clamp measurements, PregS induced an out-
wardly rectifying whole-cell current in HEK-M3 cells (Fig. 5a-b). This
TRPM3-mediated current was partially inhibited by 1 mM chloroform,
halothane and isoflurane, and almost fully abolished when these VAs
were applied at 5 mM. Sevoflurane was less effective: when applied at
1 mM, it only minimally inhibited the PregS-induced TRPM3 current,
whereas at 5 mM it evoked a marked but incomplete inhibition
(Fig. 5c). The effects of the VAs were fast and reversible (Fig. 5a).
The PregS-induced current is conducted by the canonical pore of the
TRPM3, but CIM0216 also induces the opening of an additional per-
meation pathway through the voltage-sensing domain of TRPM3 re-
sulting in the appearance of a marked inward current at negative
membrane potentials [29–31]. We found that VAs also inhibited the
opening of the alternative ion permeation pathway, when activated by
CIM0216 (Fig. 5d-f).
3.5. VAs inhibited native TRPM3 in sensory neurons of mouse dorsal root
ganglia
To study the effect of VAs on native TRPM3, we investigated sensory
neurons isolated from mouse DRGs. We used Ca2+ imaging to probe
PregS responses in the presence and absence of VAs (Fig. 6a). We
considered the PregS-responsive (PregS+) neurons as TRPM3 expres-
sing (TRPM3+) neurons. As suggested in previous studies, our results
also confirmed that some sensory neurons were directly stimulated by
VAs: 15.3%, 21%, 5.1%, and 1,8% of the DRG neurons were activated
by 1 mM halothane, chloroform, isoflurane and sevoflurane, respec-
tively (Fig. 6b). The distribution of the neurons activated by VAs was
similar in the TRPM3+ and TRPM3- population and, importantly, the
large majority of TRPM3+ neurons was not activated by VAs (VA-
neurons) (Fig. 6b). These results clearly argue for the conclusion that
VAs activated a subset of sensory neurons independently of TRPM3. To
investigate the VAs’ potential inhibitory effect on native TRPM3, we
compared the PregS evoked Ca2+ signals in the presence and absence of
VAs. We analysed only the TRPM3+ but VA- sensory neurons to
eliminate the influence of the TRPM3-independent Ca2+ signals evoked
by VAs on PregS-induced responses. In our experiments, we applied
repeated 2-minute-long pulses of PregS in the presence or absence of
VAs, as shown in Fig. 6a. Only those cells that responded to a depo-
larizing pulse evoked by 25 mM KCl at the end of the measurement
were considered as sensory neurons. We found that all of the in-
vestigated VAs applied at 1 mM decreased the PregS-induced, TRPM3-
mediated Ca2+ transients. The inhibitory effect of VAs was reversible
within 4 min after application (Fig. 6c).
Since activation of TRP channels results in depolarization of sensory
neurons, Ca2+ signals evoked by activating TRP channels may be fur-
ther amplified by the consequent activation of voltage-gated Ca2+
channels. Previous studies revealed that VAs inhibit some voltage-de-
pendent Ca2+ channels, as well [36]. Therefore, we considered, that the
inhibition of voltage-gated Ca2+ channels might contribute to the
Fig. 1. The structure and stability of the investigated volatile anaesthetics (VAs). (a)
Chemical structure of VAs investigated in this study: halothane (a halogenated
alkene), chloroform (trichloromethane), isoflurane (a halogenated methyl-ethyl
ether) and sevoflurane (fluorinated methyl-isopropyl ether). (b) The stability of
the most concentrated 10 mM stock solutions in open, freely ventilating vials
was checked by GC/MS in the given timeframe as described in the “Materials
and methods” section (n = 3 at each point).
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apparent inhibition of signals induced by PregS or agonists of other TRP
channels. To challenge the role of voltage-gated Ca2+ channels, we
tested whether or not VAs influence Ca2+ responses evoked by acti-
vating other native thermosensitive TRP channels expressed on sensory
neurons. During these experiments, we slightly modified the previous
protocol as illustrated in Fig. 6d. Because the effect of capsaicin and
AITC is poorly reversible, we applied isoflurane before and together
with the 1st agonist application, and the effect was compared to the 2nd
agonist application after the wash out of the VAs. If the inhibitory effect
of VAs experienced in our previous experiments were partially or totally
mediated by some other voltage-gated Ca2+ channels, then VAs should
also inhibit Ca2+ transients evoked by activating other TRP channels
that cause depolarization of sensory neurons. Our results refuted this
theory. The amplitudes of the Ca2+ transients activated by the TRPV1-
specific agonist capsaicin and the TRPA1 agonist AITC did not decrease
in the presence of isoflurane, whereas, the PregS-evoked Ca2+ tran-
sients were again significantly decreased (Fig. 6d-e). These results
clearly argue for the conclusion that VAs inhibit PregS-induced re-
sponses via TRPM3, without influencing voltage gated Ca2+ channels.
4. Discussion
Activation of several members of the superfamily of the voltage-
gated ion channels [37] is influenced by VAs, and a number of these
channels, in particular the hyperpolarization activated and cyclic nu-
cleotide gated channel 1 (HCN1) [38], shaker-related delayed rectifier
K+ channels (Kv1) [39] and two-pore-domain K+ channels (K2P) have
been implicated in the induction of general anaesthesia. Voltage gated
Na+ and Ca2+ channels can also be inhibited by VAs [36,40]. More-
over, recent studies reported the effect of VAs on thermosensitive TRP
channels, as well. The cold- and menthol-activated TRPM8, after an
initial activation, was inhibited by VAs. Likewise TRPC5 [41], another
cold-sensitive family member, was inhibited by halothane and chloro-
form [42]. The warmth sensor TRPM2 was not influenced by halothane
or chloroform [41], whereas the noxious heat sensor TRPV1 was sen-
sitized [25], or, if applied at higher concentration, even activated by
VAs [43]. Moreover, irritant VAs, isoflurane and desflurane directly
activated TRPA1, a general target of several irritant chemicals, whereas
the non-irritating halothane and sevoflurane did not induce TRPA1
activation [24]. These results can explain some adverse effects often
associated with general anaesthesia induced by certain VAs. Indeed,
irritant VAs evoke mechanical hyperalgesia and bronchoconstriction,
impaired respiratory pattern, augmented laryngeal C-fiber activity and
stimulate tracheal CGRP release mainly mediated by TRPA1
[24,44–46]. In our current study, we investigated the effect of VAs on
TRPM3, a less characterized thermo-nociceptive TRP channel, which
together with TRPV1 and TRPA1 play a crucial role in acute heat pain
sensation [27,28].
In contrast to the other two heat-pain sensors TRPV1 and TRPA1,
TRPM3 was found to be neither sensitized nor activated by any of the
investigated VAs. In contrast, activation of TRPM3 by both chemical
ligands and heat was markedly inhibited by the investigated VAs.
Among those, halothane was found to be the most potent, inhibiting
PregS-evoked TRPM3 activity with an IC50 of approximately 0.5 mM,
equivalent to ca. 2-times the minimal alveolar concentration (2 MAC)
that induces anaesthesia in different species [2,47]. Although the IC50
Fig. 2. Identification of different VAs as in-
hibitors of the recombinant TRPM3. (a)
Averaged Ca2+ responses (n = 5) on HEK-M3
cells evoked by 10 µM PregS (PS) in the pre-
sence of various concentrations of isoflurane,
as indicated. Compounds were added at the
indicated time points. (b) Concentration de-
pendent inhibitory effect of VAs on the re-
combinant TRPM3 activated by 10 µM PregS.
The measurements were carried out as shown
in panel (a), VAs were applied 30 s in advance
to the agonist. (c) Concentration dependent
inhibitory effect of VAs on the recombinant
TRPM3 activated by CIM0216. The measure-
ments were carried out as in panel (a) but
3 µM CIM0216 was applied instead of PregS.
(d) Dose-response relationship of PregS in the
presence and absence of various VAs, as in-
dicated in the figure. The measurements were
carried out as in panel (a), but PregS was
applied at various concentration and VAs
were applied in 1 mM. Data are presented as
mean ± SD, n = 5 in each group.
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of chloroform was slightly higher (ca. 1.67 mM), this value also cor-
responded to approximately 1.5 MAC [5]. Other VAs were less effective
in clinically relevant concentrations: the IC50 value for isoflurane
(≈1.1 mM) is equivalent to about 3 MAC, whereas the IC50 of sevo-
flurane approached 10 MAC against PregS-evoked activation. Applied
at 1 mM, each VA shifted the PregS activation curve of TRPM3 toward
higher concentrations. Again, halothane was found to be the most ef-
fective, as it increased the EC50 of PregS approximately 50-fold. Im-
portantly, at 1 mM, all investigated VAs inhibited the activation of
native TRPM3 in sensory neurons of mouse DRGs, as well. Moreover,
VAs inhibited not only the activity of TRPM3 induced by PregS, but
they also inhibited the effect of the synthetic agonist CIM0216 and the
heat-induced TRPM3 responses with very similar potencies.
The sensitivity of TRPM3 toward some VAs seems to be slightly
lower than sensitivity of ion channels generally believed to mediate
anaesthesia. Clinically relevant concentrations (≈1 MAC) of volatile
anaesthetics activate several members of the K2P channel family known
to conduct background K+ currents, which crucially contribute to the
negative membrane potential [3]. For example, the EC50 of halothane
and sevoflurane that induce TASK-1 mediated K+ currents were
Fig. 3. High concentration of halothane
induced Ca2+ signals independently of
TRPM3 and thymol used in 150 ppm as
stabilizer in halothane. (a-b)
Representative Ca2+ signals evoked by
halothane applied in high concentra-
tion in HEK-M3 (a) and HEK293T (b)
cells. (c) Statistical analysis of PregS
(PS, 10 µM) and halothane (5 mM)
induced Ca2+ signals in the presence
and absence of isosakuranetin in HEK-
M3 cells using two-tailed Student’s t-
test for independent samples.
Amplitude was measured within the
1st minute after the application of the
compounds. (d) Dose-response re-
lationship of thymol on HEK-M3 cells,
before and after applying 10 µM PregS,
as shown in panel (a-b), but thymol
was applied without halothane. Date
are presented as mean ± SD, n = 5 in
each group.
Fig. 4. VAs inhibited thermal activation of TRPM3. (a) Changes in intracellular Ca2+ concentration of HEK-M3 cells upon elevating temperature in the presence of
various concentrations of halothane as indicated in the figure. Native HEK293T cells were used as negative control. (b) Dose dependent inhibitory effect of VAs on the
recombinant TRPM3 activated by temperature shift from 37 to 43 °C. The measurements were carried out as in panel (a). Data are presented as mean ± SD, n = 5 in
each group.
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0.23 mM and 0.29 mM (near to 1 MAC), respectively [48]. Moreover,
NMDA receptor mediated currents were also effectively inhibited by
isoflurane and sevoflurane with reported IC50 values between 0.25 and
1.3 MAC and ca. 1.25 MAC, respectively [49,50]. The EC50 of isoflurane
and sevoflurane potentiating GABA induced activity of GABAA re-
ceptors was found also around 1 MAC (0.29 mM and 0.33 mM, re-
spectively) [49,51]. However, the potency of halothane inhibiting
NMDA receptor mediated postsynaptic excitatory currents
(IC50 = 0.57 mM, equivalent with ca. 2 MAC) [52] and potentiating
GABA induced GABAA currents (EC50 = 0.67 mM, ca. 2 MAC) [53]
were very close to the value we found for TRPM3.
Although we analysed the α2 variant and native channels from
mice, we strongly believe that our findings can be easily extrapolated to
native human channels which is not characterized functionally. Until
today, the best characterized variant is the mTRPM3α2 [54] which
functionally seem to be hardly distinguishable from the native mouse
and the recombinant human TRPM3: each of these variants form Ca2+-
permeable cation channels [55–57], are activated by PregS [58,59],
Fig. 5. Reversible inhibition of whole-cell TRPM3 cur-
rents by various VAs. (a) Representative time courses
illustrating the effect of PregS and chloroform on
TRPM3 mediated transmembrane currents at −80
and +120 mV. Currents were measured during a
voltage ramp from −150 to +150 mV applied at
every 2 s. (b) I/V relationship of the transmembrane
currents at different time points as indicated in panel
(a), illustrating the concentration dependent inhibi-
tion of PregS induced currents by chloroform. (c)
Statistical analysis of VAs’ effect on PregS induced
transmembrane currents (n = 5 in each group, ex-
cept in case of isoflurane, where n = 6). The mea-
surements were carried out as shown in panel (a). (d)
Representative time courses illustrating the effect of
CIM0216 and halothane on TRPM3 mediated trans-
membrane currents at −80 and +120 mV. A voltage
ramp from −150 to + 150 mV was applied at every
2 s. (e) I/V relationship of the transmembrane cur-
rents at different time points as indicated in panel
(d), illustrating the concentration dependent inhibi-
tion of CIM0216 induced currents by halothane. (f)
Statistical analysis of VAs’ effect on CIM0216 induced
transmembrane currents (n = 6, except in case of
chloroform, where n = 5). The measurements were
carried out as in panel (d). Effect of VAs was com-
pared to the agonist (PregS or CIM0216) induced
current before applying the VAs (one sample t-test,
control agonist induced current is considered as
100%). Box plots represent the range between 25 and
75 percentile values, horizontal lines mark the
median values, square symbols mark the means and
whiskers represent SD.
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and undergo very similar regulation by phosphatidylinositol 4,5-bi-
sphosphate [60,61] and by the βγ subunit of G protein coupled re-
ceptors [62–65]. Heat sensitivity is also a shared feature of the re-
combinant (mTRPM3α2) and native TRPM3 channels [27,28].
Importantly, both mouse and human TRPM3 were effectively blocked
by diclophenac and primidone [59,66]. These close functional and
pharmacological similarities suggest that our findings on mouse TRPM3
can be generalized to native human channels.
While our results indicate that VAs inhibit homotetrameric TRPM3,
potential heteromerization between different TRP channel subunits can
influence the functional characteristic of the tetramer channels, as de-
scribed for example for the thermosensitive members of the TRPV fa-
mily [67,68]. However, available data do not suggest significant par-
ticipation of TRPM3 in forming heteromeric TRP channels. Although
the closest relative TRPM1 was shown to be able to form hetero-
multimeric channels with TRPM3, TRPM4 was found not to interact
with TRPM3 [69]. Considering that expression of TRPM1 is mainly
restricted to melanocytes and retinal bipolar cells [70,71], and it is not
Fig. 6. VAs inhibited TRPM3 dependent Ca2+
transients in somatosensory neurons isolated from
mouse DRGs. (a) Representative traces showing
typical changes of intracellular Ca2+ concentra-
tion in DRG neurons from wild-type mice in re-
sponse to 20 µM PregS, 1 mM halothane, and
their combination as indicated in the panel.
25 mM KCl was used as positive control to de-
polarize the neuronal cell membrane. (b)
Percentage of DRG neurons responding to PregS
(PS+) and various VAs applied in 1 mM (VA+).
The measurements were carried out as in panel
(a). (c) Statistical analysis of VAs’ effect (1 mM
each) on PregS induced Ca2+ transients in PregS
+/VA− sensory neurons. Values are given as
percentage of the first PregS-induced Ca2+
transient without VAs. Dots represents in-
dividual neurons, and horizontal lines indicate
mean values. Effect of VAs was compared to the
vehicle treated control group by ANOVA and
Dunnett’s post-hoc test. (d) Representative traces
showing typical changes in intracellular Ca2+
concentration in DRG neurons in response to
PregS (multiple traces), AITC, and capsaicin in
the presence and absence of 1 mM isoflurane, as
indicated in the figure. (e) Statistical analysis on
the amplitude of PregS, AITC and capsaicin in-
duced Ca2+ in the presence and absence of 1 mM
isoflurane. Measurements were carried out as in
panel (d). Effect of isoflurane was compared to
transients evoked by isoflurane free agonist as
100% by one-sample t-test. Dots represents in-
dividual neurons, and horizontal lines indicate
mean values.
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expressed in mouse DRGs [72], we do not assume significant hetero-
merization which would influence the responsiveness of TRPM3 to VAs.
However, PregS and VAs induced responses may be influenced by the
presence of alternative targets expressed by sensory neurons. Indeed,
although ca. half of the sensory neurons isolated from wild type DRG
are activated by PregS and considered as TRPM3+ neurons, about 10%
of the neurons obtained from TRPM3−/− mice are also activated by
PregS [27,28] indicating the presence of TRPM3 independent me-
chanisms. This has to be considered when interpreting our experiments
carried out on sensory neurons: a low percentage of the PregS induced
responses is probably independent of TRPM3. However the exact nature
of additional target(s) is mainly elusive. Although sensory neurons of
the DRG express both NMDA and GABAA receptors, their role is ques-
tionable in PregS induced responses without their primary ligands.
Although an emerging body of evidence supports the direct action of
VAs on TRP channels, we have only a limited knowledge about the
underlying mechanisms and the potential binding sites. Studies on
TRPA1 and TRPV1 highlighted the role of the pore domain in forming
the binding pocket for VAs [43,73], although molecular dynamics si-
mulation suggested multiple binding sites on TRPV1 [74]. Our experi-
ments did not directly address the mechanism of action of VAs on
TRPM3, but we observed in our electrophysiological measurements that
VAs inhibited not only the canonical pore currents but also the alter-
native pore currents induced by CIM0216 at negative membrane po-
tential [30]. These currents are mediated by the opening of an alter-
native permeation pathway established by the voltage sensing domain
of the channel [29,31,75]. The finding that both the canonical and the
alternative pore mediated currents are blocked by VAs indicates that
VAs do not act as classical pore blockers, but rather inhibit channel
gating via a conformational change affecting activation by various
mechanisms.
Our results not only reveal an additional ion channel affected by
VAs, but also extend our knowledge about the pharmacological inter-
actions of TRPM3 that potentially modulate sensory functions mediated
by this channel. TRP channels are promising targets pursued by several
pharmaceutical companies for the development of novel drugs to
manage several, mostly pain related, clinical syndromes [22,76,77].
Despite significant efforts, several TRP-targeting drugs, in particular the
first generation of antagonists targeting TRPV1, failed in clinical trials
due to undesirable side effects such as hyperthermia and impaired
noxious heat sensation [22,78,79]. From this point of view, TRPM3
may be a safer target, since its activation by PregS, in contrast to cap-
saicin, a potent and selective activator of TRPV1 [80], did not affect
core body temperature [28]. To date, only a few blockers of TRPM3
have been characterised, and in animal models some of these were
indeed found to inhibit TRPM3-mediated pain, including the flavanone
derivative isosakuranetin [81] or the antiepileptic drug primidone [66].
Our results introduce VAs as a new class of TRPM3 inhibitors. A po-
tential advantage of VAs is that they are well established, approved
compounds and large amount of data available about their safety in
human applications. However, their slightly lower affinity to TRPM3
than to several other targets, e.g. to GABAA and K2P channels, can limit
their usage in clinical applications as TRPM3 targeting blockers. In spite
of concerns about specificity of VAs, our data provide important new
information contributing to the characterization of TRPM3 as potential
pharmacological target of novel analgesics. The knowledge about the
general mechanism of action of VAs may help identify targetable re-
gions and basic biophysical and molecular interactions which can be
utilized in future studies applying rational drug design approach. In the
other hand, characterizing VAs, as a new class of chemicals inhibiting
TRPM3 may also advance the field of pharmacochemistry of TRP
channels.
In conclusion, we characterised TRPM3 on sensory neurons as a
potential target of VAs. These findings may contribute to the better
understanding of the analgesic effect of VAs, and may aid in the further
development of TRPM3 modulators as novel analgesics.
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